Subsequently, using both published data and our experimental results, the genes in the computationally-identified signaling network were validated and indeed shown to be regulated by TMEM30A during tumor migration, laying the foundation for the development of a potential cancer therapy. This evidence concerns the gene CDC50A and neoplasm.